Company: DGLY
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001641172-25-024667
Chunk: 60

Company: DIGITAL ALLY, INC.
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
    Remaining contractual term 
     3.3 years  
     2.8 years 
  
    Exercise price 
     11,000.00 – 15,000.00  
     11,000.00 – 15,000.00  
  
    Common stock issuable under the warrants 
     562  
     562 

    32

NOTE 12 - STOCKHOLDERS’ EQUITY

February 2025 Public Equity Offering

On February 13, 2025, the
Company entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (the “Underwriter”)
for the sale and issuance of (i) 3,925 units at a public offering price per unit of $300.00 with each Unit consisting of one share of
Common Stock, one Series A warrant to purchase one share of Common Stock at an exercise price of $375.00 per share and one Series B warrant
to purchase one share of Common Stock at an exercise price of $600.00 and (ii) 46,075 pre-funded units at a public offering price of $298.00
per pre-funded unit, with each pre-funded unit consisting of one pre-funded warrant exercisable for one share of Common Stock at an exercise
price of $0.001 per share, one Series A warrant and one Series B warrant. The pre-funded warrants were immediately exercisable and may
be exercised at any time until all of the pre-funded warrants are exercised in full.

The Series A and Series B
warrants are exercisable only upon receipt of stockholder approval of (i) certain terms in the Series A and B warrants and the issuance
of the shares of Common Stock issuable upon the exercise of such Series A and Series B warrants, as may be required by the applicable
rules and regulations of The Nasdaq Stock Market LLC and (ii) if necessary, a proposal to amend the Company’s Articles of Incorporation,
to increase the authorized share capital of the Company to an amount sufficient to cover the shares of Common Stock issuable upon the
exercise of the Series A and Series B warrants. The Series A warrants will be exercisable commencing upon the date of public notice of
Stockholder Approval until five years after such date, and the Series B Warrants will be exercisable commencing upon the date of public
notice of Stockholder Approval until two and one-half years after such date.

The offering closed on February